RecruitingCardiovascular Disease

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Eligible age

50–105 yrs

Accepts

All genders

Locations

38 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).

Sponsor: Amgen

You may qualify if…

✓ Age ≥50 years
✓ Lp(a)≥ 200 nmol/L during screening
✓ Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis

You may not qualify if…

✕ Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
✕ Prior or planned arterial revascularization
✕ History of major bleeding disorder